Medtronic Expands Two Insulin Pump Recalls, Including One Over Cybersecurity Concerns

XTalks

Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks.

Researchers overcome translational gap by developing novel in vivo model for the labeling of insulin secretory granule pools

Scienmag

Pancreatic beta cells produce, store and secrete insulin upon elevated blood glucose levels. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lilly wagers up to $1B on a biotech's plan for a new type of insulin

Bio Pharma Dive

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap

Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn deal

Pharma Phorum

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. .

Researchers Develop Arthritis Vaccine + Medtronic Expands Recall on Insulin Pumps – Xtalks Life Science Podcast Ep. 32

XTalks

The editorial team also discussed Medtronic’s expanded recalls of the remote controllers for certain models of its MiniMed insulin pumps over cybersecurity concerns, as well as its 600 series insulin pumps due to a faulty retainer ring.

Insulin is necessary for repairing olfactory neurons

Scienmag

Findings point to possible treatment for smell loss Credit: Monell Chemical Senses Center, eNeuro PHILADELPHIA (May 17, 2021) – Researchers have known for some time that insulin plays a vital role in regeneration and growth in some types of neurons that relay environmental sensory information to our brains, such as sight.

FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps

The Pharma Data

approval of pump use for Lilly’s novel insulin is latest development designed to help people with diabetes manage blood sugar levels. “The expansion of the Lyumjev label to include use in an insulin pump provides a new and important choice for people with diabetes.

FDA okays Mylan insulin drug as first ‘interchangeable’ biosimilar

Pharma Phorum

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus.

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

The Pharma Data

retail pharmacies Monthly prescriptions for all Lilly insulins — including Insulin Lispro Injection — remain available for $35 through the Lilly Insulin Value Program and the Medicare Part D Senior Savings Model.

Tubeless automated insulin delivery system improves blood glucose outcomes

Scienmag

Study finds Omnipod® 5 simplifies diabetes management in type 1 diabetes WASHINGTON–People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy.

A flexible leader in cartridge processing

Syntegon Technology Pharma Blog

Liquid Dosage Pharma aseptic Cartridge Closing Filling Insulin Processing

rBIO Launches with Technology to Hyper-Produce Insulin Cost-Effectively, at Scale

BioSpace

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs

Mask-Associated Dry Eye + Droplet Micron Insulin Needle – Xtalks Life Science Podcast Ep. 1

XTalks

In Episode 1 of the Xtalks Life Science Podcast, Sarah discusses a new condition called “Mask-Associated Dry Eye” and Ayesha talks about Droplet Micron, an innovative insulin needle. And hear from Anu Rajora, director of medical marketing at HTL-STREFA, the company behind the innovative Droplet Micron insulin needle, who explains why technology needs to make it easier for patients to adhere to medication schedules.

Hybrid closed-loop insulin therapy improves glycemic control

Scienmag

publishers New Rochelle, NY, January 26, 2021–Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. Credit: Mary Ann Liebert, Inc.,

Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market

XTalks

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections.

Arecor hopes London stock market float will raise profile of insulin products

Pharma Phorum

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. The initial therapeutic focus is diabetes, with three insulin-based products in development.

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration

BioTech 365

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration Amalgam Rx™ Receives CE Mark for Basal Insulin Titration Insulin Titration App Meets Requirements for European Launch WILMINGTON, Del.–(BUSINESS –(BUSINESS WIRE)–#cemarking–Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences … Continue reading → Business Wire

2020 Report on Insulin Resistance R&D Pipeline Analysis – Small Insulin Resistance Companies Look for Licensing and Collaboration Partners – ResearchAndMarkets.com

BioTech 365

2020 Report on Insulin Resistance R&D Pipeline Analysis – Small Insulin Resistance Companies Look for Licensing and Collaboration Partners – ResearchAndMarkets.com 2020 Report on Insulin Resistance R&D Pipeline Analysis – Small Insulin Resistance Companies Look for Licensing and Collaboration Partners … Continue reading → Business Wire

Lilly's Tirzepatide Significantly Reduces A1C, Body Weight Versus Insulin Glargine

BioSpace

Eli Lilly's SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin

JAMA Internal Medicine

This cohort study compares the associations of long-acting insulin analogs and NPH insulin with the risk of severe hypoglycemia in older patients with type 2 diabetes

Insulet Expands its Offering of Omnipod DASH® Insulin Management System

BioTech 365

ACTON, Mass.–(BUSINESS

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The Pharma Data

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. The U.S.

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

BioTech 365

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial … Continue reading → GlobeNewswire

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

BioTech 365

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial … Continue reading → GlobeNewswire

Patient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet Micron

XTalks

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Insulin Needle Design and Technology.

Lilly Spends $1 Billion-Plus on Insulin Innovator Protomer

BioSpace

No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones

Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes

BioTech 365

Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes – REVITA-T2Di study is underway to evaluate the effectiveness of Revita DMR … Continue reading → Business Wire

New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin

The Pharma Data

New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. While premix ed is used by around 4 0% of people taking insulin globally to manage their type 2 diabetes today, recent real-world evidence suggests only 18.2% premixed insulin).

#news #biotech Controlling insulin production with a smartwatch

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Controlling insulin production with a smartwatch.Many modern fitness trackers and smartwatches feature integrated LEDs. The green light emitted, whether continuous or pulsed, penetrates the skin and can … Continue reading → #news

Global Oral Insulin Market Report 2021-2025: Size & Forecast with Impact Analysis of COVID-19 on Healthcare Sector, Diabetic Patients, & Oral Insulin – ResearchAndMarkets.com

BioTech 365

Global Oral Insulin Market Report 2021-2025: Size & Forecast with Impact Analysis of COVID-19 on Healthcare Sector, Diabetic Patients, & Oral Insulin – ResearchAndMarkets.com Global Oral Insulin Market Report 2021-2025: Size & Forecast with Impact Analysis of COVID-19 on Healthcare … Continue reading → Business Wire

Worldwide Rapid Acting Insulin Industry to 2027 – Sedentary and Unhealthy Lifestyles are Driving Growth – ResearchAndMarkets.com

BioTech 365

Worldwide Rapid Acting Insulin Industry to 2027 – Sedentary and Unhealthy Lifestyles are Driving Growth – ResearchAndMarkets.com Worldwide Rapid Acting Insulin Industry to 2027 – Sedentary and Unhealthy Lifestyles are Driving Growth – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Rapid Acting Insulin Market … Continue reading → Business Wire

Global Insulin Pumps Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

BioTech 365

Global Insulin Pumps Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com Global Insulin Pumps Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Insulin Pumps … Continue reading → Business Wire

$11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) – Industry Analysis Report and Forecasts – ResearchAndMarkets.com

BioTech 365

Billion Global Rapid Acting Insulin Market (2021 to 2027) – Industry Analysis Report and Forecasts – ResearchAndMarkets.com $11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) – Industry Analysis Report and Forecasts – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Rapid … Continue reading → Business Wire

In collab with Novo Nordisk, Walmart says it will ‘revolutionize’ insulin access with deep discounts

Journal for Clinical Studies

Insulin costs have been a controversial topic in pharma for years, with the leading manufacturers facing routine scrutiny for their pricing… The post In collab with Novo Nordisk, Walmart says it will ‘revolutionize’ insulin access with deep discounts appeared first on Journal for Clinical Studies.

Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine

Pharma Times

Investigational therapy also led to superior body weight reductions in adults with type 2 diabetes

Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes

BioTech 365

Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes … Continue reading → GlobeNewswire

Self-injecting pill could offer oral administration for monoclonal antibodies, insulin and other drugs

BioPharma Reporter

A new type of self-injecting capsule could deliver medications at comparable levels to those given via injection, according to a preclinical study. Bio Developments

China Recombinant Lispro Insulin Market Report 2021-2025 Featuring Lilly & Gan & Lee Pharmaceuticals – ResearchAndMarkets.com

BioTech 365

China Recombinant Lispro Insulin Market Report 2021-2025 Featuring Lilly & Gan & Lee Pharmaceuticals – ResearchAndMarkets.com China Recombinant Lispro Insulin Market Report 2021-2025 Featuring Lilly & Gan & Lee Pharmaceuticals – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Recombinant Lispro … Continue reading → Business Wire

Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe With Skewed Graduation Markings

BioTech 365

Insights on the Human Insulin Global Market to 2026 – by Product Type, Distribution Type, Disease Type and Region – ResearchAndMarkets.com

BioTech 365

Insights on the Human Insulin Global Market to 2026 – by Product Type, Distribution Type, Disease Type and Region – ResearchAndMarkets.com Insights on the Human Insulin Global Market to 2026 – by Product Type, Distribution Type, Disease Type and Region … Continue reading → Business Wire

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly’s connected insulin solutions

The Pharma Data

and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar ® insulin management solution that integrates insulin dosing data for several Lilly insulins. Welldoc, Inc.,

#news #biotech Eli Lilly’s $1B buyout bet for Protomer sees it grab the ‘next frontier’ in smart insulin tech

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Eli Lilly’s $1B buyout bet for Protomer sees it grab the ‘next frontier’ in smart insulin tech.Eli Lilly’s $1B buyout bet for Protomer sees it grab the … Continue reading → #news

Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025 – ResearchAndMarkets.com

BioTech 365

DUBLIN–(BUSINESS WIRE)–The “Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025” report has been added to ResearchAndMarkets.com’s offering. “Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025” Report Highlights: Diabetes Drug Market Opportunity: > … Continue reading → Business Wire